Allergan has constructed a network of legal defences to protect Restasis, a blockbuster with sales of around $1.5 billion a year, from generic competitors. Bryson said a new formulation involving ...

It was then that Actavis, a drug company that specializes in generic drugs and over-the-counter products, scooped up Allergan for a neat $66 billion. Here's a photo of Actavis CEO Brenton Saunders ...

Following the Actavis tie-up, Allergan sold its generic drugs business to Israel's Teva Pharmaceutical Industries in July for US$40.5 billion in cash and stock. And Saunders said after that he ...